Kodak was a satiric example, but not comparing - simply saying someone else e.g. Lonza or other cell manufacturers will be awarded not MSB. Rem-L doesn't have a patent (only pending) for Covid-ards. So it's a blessing for the world after all - no one to pay for the licensing of a remedy, only manufacturing costs (which is why we raised through BP).
Unfortunately, Lonza are the established CSL in this instance and are 40 steps ahead, already building infrastructure in China / US / Europe to manufacture. They got the inside scoop. Would've been a different game if we were the sole manufacturers.
Still have Heart and back in the game, but pre-curser cells may not be as pluripotent.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$2.31 |
Change
-0.100(4.15%) |
Mkt cap ! $2.956B | |||
| Open | High | Low | Value | Volume |
| $2.33 | $2.35 | $2.15 | $30.94M | 13.57M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 75954 | $2.30 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.32 | 10350 | 2 |
View Market Depth
| Last trade - 16.17pm 21/07/2025 (20 minute delay) ? |
| MSB (ASX) Chart |